Navigation Links
Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Date:6/3/2008

er, and senior author on the poster. "We look forward to seeing tanespimycin advance into its next set of clinical trials with the goal of elucidating its potential role in the metastatic breast cancer treatment paradigm."

"Tanespimycin is the most advanced Hsp90 inhibitor in development for HER2-positive breast cancer and has generated what we believe is highly promising data in this indication," said Pamela Cohen, M.D., Kosan's Chief Medical Officer. "We believe that Hsp90 inhibition is among the most novel and broadly applicable anticancer targets being explored today, and that it may have broad applicability in breast cancer and other cancer indications."

Phase 2 Tanespimycin Data

Tanespimycin is an Hsp90 inhibitor that has demonstrated the potential to disrupt the activity of multiple oncogenes and cell signaling pathways implicated in tumor growth, including HER2, a key pathway in breast cancer.

The objective of the Phase 2 trial is to determine the objective response rate by RECIST in patients with HER2-positive metastatic breast cancer. To be eligible for the trial, patients must have had either progressive disease within 3 months following last dose of adjuvant treatment with trastuzumab or have progressive disease following initial therapy for metastatic disease with trastuzumab (trastuzumab may have been administered with cytotoxic chemotherapy or as a single agent). Tanespimycin was administered at a dose of 450 mg/m2 following administration of the standard dose of trastuzumab.

Of 31 patients enrolled in the trial, 27 were evaluable for efficacy (as of May 15, 2008).
-- Of the 27 patients evaluable for efficacy, 17 (63%) showed

evidence of clinical benefit, including:

-- 7 patients or 26% had PR (including 1 patient with an unconfirmed

PR who remains on study)

-- 5 patients or 19% had tumor regressions (20-29% decrease)

-- 5 patients or 19% had SD of
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
2. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
3. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
4. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
7. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
8. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
9. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
10. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
11. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® ... Alpine™ Hip Stem, the latest addition to its ... Stem is intended for use in total hip ... http://photos.prnewswire.com/prnh/20140830/141676 Alpine was ... stem philosophy. ODEV,s engineers worked closely with a ...
(Date:9/2/2014)... September 2, 2014 Today, Analysts ... WLP ), Tekmira Pharmaceuticals Corporation (NASDAQ: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,WellPoint Inc. Research Reports ,WellPoint Inc. (WellPoint) posted on ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The Australian ... universal healthcare coverage and good access to facilities ... and its associated disease burden, well-defined regulatory guidelines, ... of a new manufacturing policy will drive the ... a focus on generic substitution and price cuts ...
Breaking Medicine Technology:Ortho Development Receives FDA Clearance for Alpine Hip Stem 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5
... YORK, Dec. 23, 2010 Dr. David Samadi, robotic ... of Urology, and Chief of Robotics and Minimally Invasive Surgery ... continues to break barriers by sharing his robotic surgery ... worldwide. Today, Samadi, a pioneer surgeon in the field of ...
... 23, 2010 Generex Biotechnology Corporation ( www.generex.com ) (OTC ... to extend the closing date of its previously announced acquisition ... www.globalmeddirect.com ) to June 1, 2011. The Company ... decision of the Nasdaq Listing and Hearing Review Council affirming ...
Cached Medicine Technology:Robotic Surgery Expert Dr. David Samadi, MD Travels to Israel to Perform a Live Robotic Prostatectomy 2Robotic Surgery Expert Dr. David Samadi, MD Travels to Israel to Perform a Live Robotic Prostatectomy 3Generex Announces Extension of Global Medical Direct Acquisition Closing Date 2Generex Announces Extension of Global Medical Direct Acquisition Closing Date 3
(Date:9/2/2014)... patient adherence to treatment following a myocardial infarction ... results reported at the European Society of Cardiology,s ... Principal Investigator Valentin Fuster, MD, PhD, Director of ... at Mount Sinai and General Director of the ... in Madrid, Spain, the novel fixed-dose combination drug ...
(Date:9/2/2014)... Obesity is associated with many health risks, including heart ... found a possible way to mitigate one often-overlooked risk: ... study led by Sheldon H. Jacobson, a professor of ... obesity rates are associated with a decrease in seatbelt ... laws are in effect. , "Primary seatbelt laws lead ...
(Date:9/2/2014)... Betmiga) has been approved since December 2012 for the ... benefit assessment pursuant to the Act on the Reform ... Institute for Quality and Efficiency in Health Care (IQWiG) ... over the appropriate comparator therapy specified by the Federal ... regard to side effects: Dry mouth was less common ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Welcome to ... the over 4.6 million Canadians living with the disease, ... “Voices of Arthritis” video series featuring well-known Canadians from ... ,      Lloyd Robertson , veteran news ... silver medal skier ,      Amy Cotton ...
(Date:9/2/2014)... has become an increasing concern to health officials both ... City Department of Health and Mental Hygiene, the number ... triple the number of such deaths in 2000. Much ... rise in nonmedical prescription opioid (PO) use among teens ... among youth who transitioned from POs to heroin. ...
Breaking Medicine News(10 mins):Health News:New polypill increases heart attack patients' medication adherence 2Health News:New polypill increases heart attack patients' medication adherence 3Health News:Seatbelt laws encourage obese drivers to buckle up 2Health News:Mirabegron for overactive bladder: Added benefit not proven 2Health News:Mirabegron for overactive bladder: Added benefit not proven 3Health News:‘Voices of Arthritis’ Launches Awareness Month 2Health News:‘Voices of Arthritis’ Launches Awareness Month 3Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3
... John Brumby today announced a $100 million (AUD) ... supercomputer facility to assist in discovering cures and ... brain disorders and ,flu pandemics. , In making ... at UC San Diego, Premier Brumby said the ...
... RICHMOND, Calif., June 18 Transcept,Pharmaceuticals, Inc. today ... Officer, will present at the Jefferies 2nd Annual,Healthcare ... 25, 2008 at 9:30,AM Eastern Time., The ... http://www.wsw.com/webcast/jeff26/transcept ., About Transcept Pharmaceuticals, Transcept ...
... Accuray,Incorporated (Nasdaq: ARAY ), a global leader ... and chief executive officer, Euan S.,Thomson, Ph.D., is scheduled ... 26, 2008 at 10:15 a.m. EDT (7:15 a.m. PDT)., ... available online from the,investor relations page of the Company,s ...
... 18 The Quantum Group,Inc. (Amex: QGP ) ... for the second quarter of fiscal 2008 ended April ... 2008, the Company reported an increase,in revenues of approximately ... of fiscal year 2007. On a sequential basis compared ...
... FORT LAUDERDALE, Fla., June 18 eDiets.com,Inc. (Nasdaq: ... to bring diet,fitness and healthy lifestyle solutions to ... Information Officer effective immediately.,Bringing over 8 years of ... as the CIO and VP of IT at ...
... leader in,providing automated, molecular testing solutions, announced today ... for Human papillomavirus. Patent No.1,499 749 B1, "Human ... method for detecting the presence of HPV using ... of our collaboration with Dr. Erik,Thunnissen, a prominent ...
Cached Medicine News:Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 2Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 3Health News:Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference 2Health News:Accuray Incorporated's CEO to Speak at Jefferies Second Annual Healthcare Conference 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 3Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 4Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 2Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 3
... The 8600 Series Tabletop/Portable Digital ... universal tool for patient monitering. ... monitoring, the 8600 has earned ... worldwide and is recognized for ...
Halogen-free immersion oil based on ester oil....
Immersion oil composed on polyester polyol, diphenyl cresyl phosphate and tricyclodecane dimethanol....
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
Medicine Products: